TY - JOUR
T1 - Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016
T2 - antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus
AU - Hayami, Hiroshi
AU - Takahashi, Satoshi
AU - Ishikawa, Kiyohito
AU - Yasuda, Mitsuru
AU - Yamamoto, Shingo
AU - Wada, Koichiro
AU - Kobayashi, Kanao
AU - Hamasuna, Ryoichi
AU - Minamitani, Shinichi
AU - Matsumoto, Tetsuya
AU - Kiyota, Hiroshi
AU - Tateda, Kazuhiro
AU - Sato, Junko
AU - Hanaki, Hideaki
AU - Masumori, Naoya
AU - Nishiyama, Hiroyuki
AU - Miyazaki, Jun
AU - Fujimoto, Kiyohide
AU - Tanaka, Kazushi
AU - Uehara, Shinya
AU - Matsubara, Akio
AU - Ito, Kenji
AU - Hayashi, Kenji
AU - Kurimura, Yuichiro
AU - Ito, Shin
AU - Takeuchi, Toshimi
AU - Narita, Harunori
AU - Izumitani, Masanobu
AU - Nishimura, Hirofumi
AU - Kawahara, Motoshi
AU - Hara, Makoto
AU - Hosobe, Takahide
AU - Takashima, Kenji
AU - Chokyu, Hirofumi
AU - Matsumura, Masaru
AU - Ihara, Hideari
AU - Uno, Satoshi
AU - Monden, Koichi
AU - Sumii, Toru
AU - Kawai, Shuichi
AU - Kariya, Satoru
AU - Sato, Takashi
AU - Yoshioka, Masaru
AU - Kadena, Hitoshi
AU - Matsushita, Shinji
AU - Nishi, Shohei
AU - Hosokawa, Yukinari
AU - Shirane, Takeshi
AU - Yoh, Mutsumasa
AU - Watanabe, Syuji
AU - Makinose, Shinichi
AU - Uemura, Tetsuji
AU - Goto, Hirokazu
N1 - Funding Information:
Kazuhiro Tateda has received speaker's honorarium from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co. Ltd., research funding from PAREXEL International Corp., Maruho Co., Ltd., Nissui Pharmaceutical Co., Ltd., Eiken Chemical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nippon Becton Dickinson Co., Ltd., Asahi Kasei Pharma Corporation, Eidia Co., Ltd., Kaneka Corporation, Spero Opco, Inc., Shimadzu Corporation and Hitachi, Ltd., scholarship donations from Taisho Toyama Pharmaceutical Co. Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc. and Toyama Chemical Co., Ltd., and has an endowed department sponsored by Meiji Seika Pharma Co., Kyorin Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co. Ltd. and MSD K.K.
Funding Information:
Shin Ito has received research funding from Wako Pure Chemical Industries, Ltd. and Hologic Japan, Inc.
Funding Information:
This investigation was supported by grants from following pharmaceutical companies (alphabetical order): Astellas Pharma , Chugai Pharmaceutical , Daiichi-Sankyo , Daito Pharmaceutical Co., Ltd. , Fujifilm Pharma Co.,Ltd . Glaxo SmithKline K. K., Kobayashi Kako Co., Ltd. , Kyorin Pharmaceutical Co., Ltd. , Maruho Co., Ltd. , Meiji Seika Pharma , MSD K.K., Nichi-Iko Pharmaceutical Co., Ltd. , Nihon Pharmaceutical Industry Co., Ltd. , Nipro Corporation , Ohara Pharmaceutical Co., Ltd. , Pfizer Japan , Sawai Pharmaceutical Co., Ltd. , Shionogi , Sumitomo Dainippon Pharma Co., Ltd. , Taiho Pharmaceutical , Taisho Pharmaceutical Co., Ltd. , Takata Pharmaceutical Co., Ltd. , Takeda Pharmaceutical Co., Ltd. , Tatsumi Kagaku Co., Ltd. , Towa Pharmaceutical Co., Ltd. , Toyama Chemical Co., Ltd . and Yoshindo Inc .
Funding Information:
This investigation was supported by grants from following pharmaceutical companies (alphabetical order): Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo, Daito Pharmaceutical Co. Ltd., Fujifilm Pharma Co.Ltd. Glaxo SmithKline K. K. Kobayashi Kako Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Maruho Co. Ltd., Meiji Seika Pharma, MSD K.K. Nichi-Iko Pharmaceutical Co. Ltd., Nihon Pharmaceutical Industry Co. Ltd., Nipro Corporation, Ohara Pharmaceutical Co. Ltd., Pfizer Japan, Sawai Pharmaceutical Co. Ltd., Shionogi, Sumitomo Dainippon Pharma Co. Ltd., Taiho Pharmaceutical, Taisho Pharmaceutical Co. Ltd., Takata Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Tatsumi Kagaku Co. Ltd., Towa Pharmaceutical Co. Ltd., Toyama Chemical Co. Ltd. and Yoshindo Inc. We are grateful to T. Nakae at the Kitasato Institute (Tokyo, Japan) for their encouragements on microbiological testing and Y. Suzuki, H. Endo, and Y. Matsui for their technical assistance in this surveillance.
Funding Information:
Shingo Yamamoto has received speaker's honorarium from Astellas Pharma Inc. and Daiichi Sankyo Co., Ltd., and received scholarship donations from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., and Bayer Yakuhin, Ltd.
Publisher Copyright:
© 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2019/6
Y1 - 2019/6
N2 - The Japanese Surveillance Committee conducted a second nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for acute uncomplicated cystitis (AUC) in premenopausal patients aged 16–40 years old at 31 hospitals throughout Japan from March 2015 to February 2016. In this study, the susceptibility of causative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus saprophyticus) for various antimicrobial agents was investigated by isolation and culturing of organisms obtained from urine samples. In total, 324 strains were isolated from 361 patients, including E. coli (n = 220, 67.9%), S. saprophyticus (n = 36, 11.1%), and K. pneumoniae (n = 7, 2.2%). The minimum inhibitory concentrations (MICs) of 20 antibacterial agents for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. At least 93% of the E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, whereas 100% of the S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing E. coli strains were 6.4% (13/220) and 4.1% (9/220), respectively. The antimicrobial susceptibility of K. pneumoniae was retained during the surveillance period, while no multidrug-resistant strains were identified. In summary, antimicrobial susceptibility results of our second nationwide surveillance did not differ significantly from those of the first surveillance. Especially the numbers of fluoroquinolone-resistant and ESBL-producing E. coli strains were not increased in premenopausal patients with AUC in Japan.
AB - The Japanese Surveillance Committee conducted a second nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for acute uncomplicated cystitis (AUC) in premenopausal patients aged 16–40 years old at 31 hospitals throughout Japan from March 2015 to February 2016. In this study, the susceptibility of causative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus saprophyticus) for various antimicrobial agents was investigated by isolation and culturing of organisms obtained from urine samples. In total, 324 strains were isolated from 361 patients, including E. coli (n = 220, 67.9%), S. saprophyticus (n = 36, 11.1%), and K. pneumoniae (n = 7, 2.2%). The minimum inhibitory concentrations (MICs) of 20 antibacterial agents for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. At least 93% of the E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, whereas 100% of the S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing E. coli strains were 6.4% (13/220) and 4.1% (9/220), respectively. The antimicrobial susceptibility of K. pneumoniae was retained during the surveillance period, while no multidrug-resistant strains were identified. In summary, antimicrobial susceptibility results of our second nationwide surveillance did not differ significantly from those of the first surveillance. Especially the numbers of fluoroquinolone-resistant and ESBL-producing E. coli strains were not increased in premenopausal patients with AUC in Japan.
KW - Acute uncomplicated cystitis
KW - Resistance
KW - Surveillance
KW - Susceptibility
UR - http://www.scopus.com/inward/record.url?scp=85063114065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063114065&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2019.02.021
DO - 10.1016/j.jiac.2019.02.021
M3 - Article
C2 - 30905628
AN - SCOPUS:85063114065
SN - 1341-321X
VL - 25
SP - 413
EP - 422
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 6
ER -